66. IgA nephropathy
199 clinical trials,   214 drugs   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-004507-31-FR
(EUCTR)
27/01/201702/02/2017N/AN/A - TIGER
MedDRA version: 19.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders
Trade Name: METHYLPREDNISOLONE MYLAN Générique
Product Name: METHYLPREDNISOLONE MYLAN Générique
INN or Proposed INN: Methylprednisolone
Other descriptive name: Methylprednisolone
Trade Name: PREDNISONE ARROW 20mg
Product Name: PREDNISONE ARROW 20mg
INN or Proposed INN: PREDNISONE
Other descriptive name: PREDNISONE
Trade Name: PREDNISONE ARROW 5 mg
Product Name: PREDNISONE ARROW 5 mg
INN or Proposed INN: Prednisone 5 mg
Other descriptive name: Prednisone 5 mg
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
122Phase 3France
2NCT02647255
(ClinicalTrials.gov)
March 201621/12/2015Trial of Plasma Exchange for Severe Crescentic IgA NephropathyRandomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)Glomerulonephritis, IGA;Kidney Diseases;Acute Renal Insufficiency;Rapidly Progressive GlomerulonephritisProcedure: Plasma Exchange (PE);Drug: Methylprednisolone pulsePeking University First HospitalNULLEnrolling by invitation14 Years65 YearsAll150Phase 2;Phase 3China
3NCT02160132
(ClinicalTrials.gov)
June 20143/6/2014A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid NephropathyDrug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intravenously in the 1st-3rd-5th month)Sun Yat-sen UniversityNULLRecruiting14 Years65 YearsBoth180Phase 2China
4NCT01560052
(ClinicalTrials.gov)
April 201215/3/2012Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose StudyIgA GlomerulonephritisDrug: methylprednisolone;Drug: PlaceboThe George InstitutePeking University First HospitalActive, not recruiting18 YearsN/AAll503N/AAustralia;Canada;China;Hong Kong;India;Malaysia
5ChiCTR-TRC-09000607
2008-12-012009-11-28Observation for Efficacy of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathyEfficacy Observation of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy IgA nephropathyA:Methylprednisolone 0.4mg/kg * 8 weeks, reduction to 5mg / d to maintain, MMF 0.75 bid * 6 months after the reduction (weight <50kg, MMF0.5 bid);B:ethylprednisolone 0.4mg/kg*8 weeks, reduction to 5mg / d to maintain;Zhongshan Hospital of Fudan UniversityNULLCompleted1870BothA:40;B:40;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-000871-41-DE
(EUCTR)
24/01/200827/11/2007Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgANSupportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN IgA nephropathy (IgAN) as the most common type of glomerulonephritis.
MedDRA version: 16.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders
Product Name: Azathioprine
INN or Proposed INN: AZATHIOPRINE
Product Name: Cyclophosphamid
INN or Proposed INN: CYCLOPHOSPHAMIDE
Product Name: Prednisolon
INN or Proposed INN: PREDNISOLONE
Product Name: Methylprednisolon
INN or Proposed INN: METHYLPREDNISOLONE
Product Name: supportive therapy
RWTH AachenNULLNot RecruitingFemale: yes
Male: yes
148Germany
7NCT00657059
(ClinicalTrials.gov)
September 20078/4/2008Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)IgA NephropathyDrug: irbesartan;Drug: methylprednisolone (MP) or prednisone (pred);Drug: mycophenolate mofetil (MMF)Sun Yat-sen UniversityNULLCompleted14 Years60 YearsAll151Phase 3China
8JPRN-UMIN000000593
2006/11/0105/02/2007Randomized controlled trial of mizoribine for progressive IgA nephropathy IgA nephropathy with moderate to severe histological alterationsMethylprednisolone pulse therapy followed by oral prednisolone administration
Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration
West Japan Study Group for Therapy of IgA NephropathyNULLComplete: follow-up complete15years-old60years-oldMale and Female120Not selectedJapan
9NCT01392833
(ClinicalTrials.gov)
December 19995/7/2011Steroids and Azathioprine in Advanced IgANSteroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter TrialIgA Nephropathy;Chronic Kidney DiseaseDrug: methylprednisolone;Drug: azathioprine;Drug: prednisoneA. Manzoni HospitalNULLCompleted16 Years70 YearsBoth46Phase 3NULL
10NCT00367562
(ClinicalTrials.gov)
January 199622/8/2006Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA NephropathyPhase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA NephropathyIGA NephropathyDrug: ENALAPRIL VALSARTAN METHYLPREDNISONEHospital BritanicoNULLCompleted21 Years70 YearsBoth20Phase 4Argentina